Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer.

Tarlatamab has been approved for patients with recurrent extensive-stage small-cell lung cancer (ES-SCLC). However, it is associated with adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Limited data exist on the concurrent occurrence of ICANS and other treatment-related adverse events. In our case study, we observed the synchronous occurrence of interstitial lung disease (ILD) and ICANS following tarlatamab initiation in recurrent ES-SCLC.